Clinical Focus


  • Pediatric Rehabilitation Medicine

Academic Appointments


Professional Education


  • Board Certification: American Board of Physical Medicine and Rehabilitation, Pediatric Rehabilitation Medicine (2019)
  • Board Certification: American Board of Physical Medicine and Rehabilitation, Pain Medicine (2018)
  • Board Certification: American Board of Pediatrics, Pediatrics (2023)
  • Fellowship: Cincinnati Childrens Hospital Pediatric Pain Medicine Fellowship (2018) OH
  • Residency: Cincinnati Children's Hospital Physical Medicine and Rehabilitation Residency (2017) OH
  • Medical Education: Rutgers New Jersey Medical School Office of the Registrar (2012) NJ

All Publications


  • Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study PEDIATRIC DERMATOLOGY Hartzell, C. J., Szabova, A., Collins, A. B., Morel, A. N., Mijatovic, D., Goldschneider, K. R. 2024

    Abstract

    At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.Aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.

    View details for DOI 10.1111/pde.15704

    View details for Web of Science ID 001275953500001

    View details for PubMedID 39049669